Abstract
Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the 'right' treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.
Original language | English |
---|---|
Article number | 189 |
Journal | Journal of Experimental and Clinical Cancer Research |
Volume | 35 |
Issue number | 1 |
DOIs | |
Publication status | Published - Dec 5 2016 |
Keywords
- Immunosuppressed mice
- Orthotopic
- Patient-derived-xenografts
- Predictive value
- Subcutaneous
- Tumor heterogeneity
ASJC Scopus subject areas
- Oncology
- Cancer Research